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Efforts to successfully restore life in cardiac arrest victims are formidably challenging. They require not only that cardiac 
activity be initially reestablished but that injury to vital organs be prevented or minimized. In this article, we discuss the effects
that cardiac arrest and resuscitation have on the myocardium, describing first the functional myocardial abnormalities that 
occur during cardiac resuscitation, which may limit the ability to reestablish cardiac activity.  We then discuss strategies for
minimizing myocardial injury and examine novel therapies aimed at minimizing ischemia and reperfusion injury. Finally, we 
discuss sodium-hydrogen exchanger isoform-1(NHE-1) inhibitors and erythropoietin for maintaining myocardial function 
during cardiopulmonary resuscitation.
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Myocardial Ischemic Injury 
during Cardiac Resuscita-
tion
The working heart is a highly metabolic 
organ that under normal resting condi-
tions extracts nearly 70% of the oxygen 
supplied by the coronary circulation 
(1,2) representing close to 10% of the 
total body oxygen consumption. Howe-
ver, the heart has minimal capability for 
extracting additional oxygen, such that 
increases in metabolic demands can 
only be met by autoregulatory increases 
in coronary blood flow through vasodi-
latation of the coronary circuit. (3) Con-
sequently, a severe energy imbalance 
develops when cardiac arrest occurs 
and coronary blood flow ceases. The 
severe energy imbalance continues 
during the ensuing resuscitation effort 
when current closed-chest resuscitati-
on techniques are used because of the 
very limited capability for generating 
systemic and coronary blood flow. (4)
The magnitude of the energy imba-
lance is contingent on the metabolic 
requirements and is particularly severe 
in the presence of ventricular fibrillation 
(VF) when the oxygen requirements are 
comparable to or exceed those of the 
normally beating heart. (5,6) A lesser 
energy deficit is expected during cardi-
ac arrest with a quiescent or minimally 
active heart (i.e., asystole or pulseless 
electrical activity precipitated by asp-
hyxia or exsanguinations). Moreover, 
with reperfusion during resuscitati-
on, multiple pathogenic mechanisms 
 collectively known as “reperfusi-
on injury” – are activated and further 
contribute to myocardial injury. Main 
contributors to reperfusion injury are 
mitochondrial Ca2+ overload (7,8) and 
generation of reactive oxygen species 
(ROS). (9)
The limited oxygen supply and conco-
mitant reperfusion injury compromise 
the mitochondrial capability for rege-
nerating ATP (adenosine triphospha-
te) through oxidative phosphorylation. 
Limited amounts of ATP; however, are 
generated at the substrate level from 
anaerobic glycolysis and breakdown 
of creatine phosphate. Taking these 
processes together, the myocardium 
develops a marked increase in lactic 
acid, rapid depletion of creatine phosp-
hate, and relatively slow depletion of 
ATP during cardiac arrest and resus-
citation. (10) Accordingly, the resusci-
tation effort typically proceeds  and 
occasionally succeeds  in the pre-
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sence of ischemia and in the midst of 
reperfusion injury.
Various functional myocardial abnor-
malities develop, consequent to ische-
mia and reperfusion, during cardiac 
arrest and resuscitation that exert 
effects detrimental to cardiac resus-
citation. These abnormalities can be 
grouped into those that manifest during 
the resuscitation effort and those that 
manifest after the return of sponta-
neous circulation. The former include 
reductions in left ventricular myocardial 
distensibility and increased resistan-
ce to electrical defibrillation; the latter 
include reperfusion arrhythmias and 
post-resuscitation myocardial dysfun-
ction. This discussion is focused on 
reductions in left ventricular myocardial 
distensibility and the extent to which its 
prevention can improve resuscitation 
and survival.
Reductions in Left Ventricu-
lar Myocardial Distensibili-
ty during Cardiac Resusci-
tation
Preclinical evidence
Studies in various animal models of VF 
and resuscitation have shown progre-
ssive thickening of the left ventricular 
wall accompanied by parallel reducti-
ons in the left ventricular cavity witho-
ut changes in intracavitary pressures 
during the resuscitation effort. (11,12) 
A functionally similar phenomenon  
known as ischemic contracture  was 
reported in the early seventies during 
open heart surgery when operations 
were conducted under normothermic 
conditions and in fibrillating hearts 
(13,14) and more recently after pro-
longed intervals of untreated VF. (15) 
However, ischemic contracture is asso-
ciated with profound reductions in myo-
cardial ATP and often leads to a “stony 
heart” heralding irreversible ischemic 
injury. (16)
Reductions in left ventricular myocar-
dial distensibility, observed during car-
diac resuscitation, is a different phe-
nomenon: 1) it occurs much earlier 
than the “stony heart”, 2) the onset and 
subsequent progression coincide with 
the interval of reperfusion during resus-
citation, (11,17) 3) it is associated with 
less ATP depletion, (10) 4) it has been 
attributed to myocardial energy deficit 
compounded by cytosolic and mito-
chondrial Ca2+ overload precluding 
complete relaxation of individual cardi-
omyocytes, 5) it evolves into diastolic 
dysfunction upon return of spontane-
ous circulation, (18) and 6) it is largely 
reversible. (19)
There are important hemodynamic con-
sequences. As blood returns to the heart 
during the relaxation phase of chest 
compression, distensible ventricles are 
important to properly accommodate 
the returning blood and establish an 
adequate preload for the subsequent 
compression. The larger the distensibi-
lity, the larger the preload, and the larger 
the amount of blood that can be ejected 
by chest compression. This mechanism 
is akin to the Frank-Starling Law of the 
beating heart and presumes that blood 
is ejected from the left ventricle into 
the aorta during chest compression. 
Several experimental and clinical stu-
dies – using echocardiography – have 
documented that the heart is indeed 
compressed between the anterior chest 
wall and the spine and that during com-
pression the mitral valve closes and the 
aortic valve opens. (20-22)
Progressive decreases in left ventricular 
myocardial distensibility during chest 
compression contribute to progressive 
decline in the hemodynamic efficacy 
of closed-chest resuscitation. Studies 
in a porcine model of VF have shown 
that the severity of this phenomenon is 
proportional to the duration of untrea-
ted VF. (11) 
Work in our laboratory demonstrates 
that reductions in left ventricular myo-
cardial distensibility can be preven-
ted by pharmacologic interventions 
targeting reperfusion injury resulting 
in hemodynamically more stable clo-
sed-chest resuscitation. (17,23) In our 
work we showed that progressive left 
ventricular wall thickening with reduc-
tions in cavity size were mitigated by 
administration of the sodium-hydrogen 
exchanger isoform-1 (NHE-1) inhibitor 
cariporide. (17) This effect prevented 
the hemodynamic deterioration that 
characteristically occurs during chest 
compression maintaining a stable 
coronary perfusion pressure above the 
resuscitability threshold of 10 mmHg 
in pigs yielding higher resuscitation 
rates. (17) 
Clinical evidence
Takino and Okada (24) reported in 
1996 on 59 adult patients who suffe-
red non-traumatic out-of-hospital car-
diac arrest and underwent open-chest 
direct manual cardiac compression in 
the emergency department after failure 
of closed-chest resuscitation. A “firm” 
myocardium was noticed during manu-
al cardiac compression in 36 cases 
affecting predominantly the left ventric-
le. In the remaining 23 cases the hearts 
were “soft.” They also noted that some 
hearts became “firm” during compre-
ssion.
The presence of a “firm” myocardi-
um was associated with reduced 
hemodynamic efficacy of cardiac com-
pression as evidenced by a lower end-
tidal CO2 tension (PETCO2)  which is 
a well documented surrogate measu-
rement of systemic and regional blood 
flow during cardiac resuscitation. (4,25-
27) Hearts with “very firm” myocardium 
never regained spontaneous contrac-
tions. Hearts with “less firm” myocar-
dium showed some, albeit insufficient, 
spontaneous contractions. Hearts with 
“soft” myocardium regained contracti-
ons and were able to generate a perip-
heral pulse in most instances.
Other Myocardial Abnorma-
lities during Resuscitation
Notwithstanding the focus of the pre-
sent discussion on left ventricular myo-
cardial distensibility, the abnormalities 
succinctly described below share a 
common pathophysiological thread. 
Thus, interventions exerting an effect on 
left ventricular myocardial distensibility 
could also affect: 
1) resistance to defibrillation (29)
2) reperfusion arrhythmia (30) 
3) post-resuscitat ion myocardial 
dysfunction as previously reported to 
be the case associated with administra-
tion of NHE-1 inhibitors. (31-35)
Work in our research laboratory and 
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subsequent clinical work in collabora-
tion with Dr. Štefek Grmec, MD, PhD 
in Maribor, Slovenia demonstrates that 
these myocardial abnormalities in left 
ventricular dysfunction can be amelio-
rated by pharmacological intervention. 
We propose that this approach may 
represent a novel concept in resusci-
tation leading to new therapeutic inter-
ventions.
Therapeutic Interventions
Two lines of research, pointing to inhi-
bitors of the NHE-1 and to erythropoi-
etin as supporting the feasibility of the 
proposed approach, are discussed in 
this section. One line relates to work 
using NHE-1 inhibitors in various ani-
mal models of cardiac arrest over 
a period of approximately 10 years. 
(10,17,23,28,36-55) Research over the 
last decade in our laboratory using vari-
ous translational rat and pig models of 
cardiac arrest has shown consistent 
myocardial benefit associated with inhi-
bition of NHE-1 activity during resusci-
tation from VF. (10,17,23,28,37-41,56-
60) Mechanistically, these benefits are 
associated with less cytosolic Na+ 
overload, less mitochondrial Ca2+ 
overload, and preservation of oxidative 
phosphorylation. The other relates to 
more recent work using erythropoietin 
in a rat model of cardiac arrest (42) 
and in a small clinical study in patients 
suffering out-of-hospital cardiac arrest. 
(43) Both lines of research support the 
rationale and feasibility of using either 
an NHE-1 inhibitor or erythropoietin for 
preservation of left ventricular myocar-
dial distensibility during cardiac resus-
citation.
Effects of NHE-1 inhibition on resusci-
tation: Research over the last decade 
in our laboratory using various tran-
slational rat and pig models of cardiac 
arrest has shown consistent myocardi-
al benefit associated with inhibition of 
NHE-1 activity during resuscitation from 
VF. (10,17,23,28,37-41,56-60) Mecha-
nistically, these benefits are associated 
with less cytosolic Na+ overload, less 
mitochondrial Ca2+ overload, and pre-
servation of oxidative phosphorylation. 
Some of these studies, highlighting 
key aspects of NHE-1 inhibition during 
resuscitation, are succinctly discussed 
below.
The initial findings suggesting that 
NHE-1 inhibit ion could attenuate 
reductions in left ventricular myocardial 
distensibility during resuscitation and 
also prevent post-resuscitation diasto-
lic dysfunction were made in an isola-
ted (Langendorff) rat model of VF and 
simulated resuscitation. (37,38) 
Subsequent studies were conducted in 
an intact rat model of VF and closed-
chest resuscitation and these studies 
also suggested that higher coronary 
perfusion pressures could be gene-
rated when administering a vasopre-
ssor agent given the larger blood flow 
generated in the presence of an NHE-1 
inhibitor for a given compression depth. 
This was the case when cariporide was 
combined with epinephrine in our pig 
model (28) and when combined with 
epinephrine and with vasopressin in our 
rat model. (40)
Like in previous studies which used  the 
NHE-1 inhibitor cariporide, (17) zoni-
poride also prevented reductions in 
left ventricular myocardial distensibili-
ty during the interval of VF and extra-
corporeal circulation, which in control 
pigs was characterized by progressive 
reductions in cavity size and progressi-
ve thickening of the left ventricular wall.
These energy effects are consistent 
with NHE-1 inhibition protecting mitoc-
hondrial bioenergetic function  proba-
bly as a result of limiting mitochondrial 
Ca2+ overload  and supportive of 
the concept that left ventricular myocar-
dial distensibility during resuscitation 
is likely to be preserved by activating 
mitochondrial mechanisms capable of 
maintaining bioenergetic function.
Erythropoietin
Cell mechanism: Erythropoietin is a 
30.4-kDa glycoprotein best known for 
its action on erythroid progenitor cells 
and regulation of circulating red cell 
mass. However, several studies have 
recently shown that erythropoietin also 
activates potent cell survival mechani-
sms during ischemia and reperfusion 
through genomic and non-genomic 
signaling pathways in a broad array of 
organs and tissues including the heart, 
(61-66) brain, (67,68) spinal cord, (69) 
retina, (70) kidney, (71) liver, (72) and 
skin. (73)
Activation of these protective mechani-
sms involves binding of erythropoietin 
to a specific cell membrane receptor, 
member of the type-I superfamily of 
single-transmembrane cytokine recep-
tors, prompting cross-phosphorylation 
and activation of Janus tyrosine kinases 
(JAK) 1 and 2. Activation of JAK causes 
phosphorylation of tyrosine residues 
creating docking sites for the recrui-
tment and activation of multiple signa-
ling proteins that have Src-homology-2 
(SH2) domains resulting in well-esta-
blished anti-apoptotic, (62) anti-inflam-
matory, (74,75) and proliferative effects 
(i.e., neovascularization) (76,77) with 
time courses that vary contingent on the 
specific signaling mechanism and the 
duration of the erythropoietin binding to 
the EpoR (erythropetine receptors).
Although important in other settings, 
these effects are not likely to play a 
role for initial cardiac resuscitation. 
We hypothesize that erythropoietin is 
important for resuscitation by signaling 
through pathways that result in preser-
vation of mitochondrial bioenergetic 
function leading to functional effects 
similar to those elicited by NHE-1 inhi-
bition (albeit through quite distinct cell 
mechanisms). These mechanisms  
we hypothesize  involve activation of 
protein kinase C epsilon (PKC) and 
protein kinase B (Akt) as succinctly des-
cribed below.
PKC activation is a well established 
mechanism of myocardial protection 
believed to be responsible for pre-
conditioning and acute protection. 
(78) PKC is primarily located in the 
cytosol. Its phosphorylation by eryt-
hropoietin prompts translocation to the 
mitochondria where it could: 1) open 
putative mitochondrial ATP-sensitive 
K+ channels (KATP channels), (79,80) 
2) activate cytochrome c oxidase, (81) 
3) activate aldehyde dehydrogenase, 
(82) and 4) inhibit the mitochondrial 
permeability transition pore. (83) Ope-
ning of KATP channels increases mito-
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chondrial K+ conductivity. This is an 
energetically advantageous (84,85) 
effect likely to limit mitochondrial Ca2+ 
overload (86) exerting effects similar to 
those of NHE-1 inhibition. Activation of 
cytochrome c oxidase (complex IV of 
the respiratory electron transport chain) 
could improve the efficiency of electron 
flow from cytochrome c to molecular 
oxygen enhancing the capability for 
ATP synthesis. Activation of aldehyde 
dehydrogenase (ADH2) could redu-
ce the formation of toxic HNE-Michael 
adducts (4-hydroxy-trans-2-nonenal 
Michael adducts) and serve to preserve 
mitochondrial respiration.
Akt activation is a powerful survival 
signal that has been shown to medi-
ate myocardial protection during late 
preconditioning and after reperfusi-
on. (87) Erythropoietin mediates the 
phosphorylation of Akt through phosp-
horylation of phosphoinositide depen-
dent kinase-1 (PDK1) upon activation 
of phosphatidylinositide kinase (PI3K). 
Activated Akt can translocate to mito-
chondria where it has been shown to 
exert beneficial effects including: 1) 
opening of mitochondrial KATP cha-
nnels (87) with the anticipated effects 
as described above, 2) activation of 
respiratory chain complexes and FoF1 
ATPase, (88) and 3) inhibition of the 
mitochondrial permeability transition 
pore.  (89)
Effects on resuscitation
Studies in rats: The effects of erythro-
poietin were studied in our rat model 
of VF and closed-chest resuscitation 
using human recombinant erythropoi-
etin (epoetin alpha, Amgen, Thousand 
Oaks, CA). (42) Rats were subjected to 
10 minutes of untreated VF followed by 
8 minutes of closed-chest resuscitation 
before attempting defibrillation. The 
depth of compression was adjusted 
to maintain an aortic diastolic pressure 
between 26 and 28 mmHg. This level 
of diastolic aortic pressure secured a 
coronary perfusion pressure above the 
resuscitability threshold of 20 mmHg 
in rats. The relationship between the 
coronary perfusion pressure and com-
pression depth (CPP/Depth) was used 
to assess changes in left ventricular 
myocardial distensibility. Successfully 
resuscitated rats were observed for 120 
minutes before euthanasia.
Three groups of 10 rats each were ran-
domized to receive a right atrial bolus 
of epoetin alpha (5,000 IU/kg) at base-
line 15 minutes before induction of 
VF (EPOBL -15-min), at 10 minutes of 
VF before starting chest compression 
(EPOVF 10-min), or to receive 0.9% 
NaCl solution (control) instead with 
the investigators blind to the treatment 
assignment.
Erythropoietin given coincident with 
the beginning of chest compression 
after 10 minutes of untreated VF – but 
not before inducing VF – promoted 
hemodynamically more effective chest 
compression such that the CPP/Depth 
ratio averaged during the interval of 
chest compression was 2.0 ± 0.3 
mmHg/mm in EPOVF 10-min, 1.6 ± 0.2 
mmHg/mm in EPOBL -15-min, and 1.6 
± 0.3 mmHg/mm in the control group 
(p < 0.05 EPOVF 10-min vs EPOBL 
-15-min and vs control). This difference 
represented a 25% improvement in the 
hemodynamic efficacy of chest com-
pression with erythropoietin given at the 
beginning of chest compression.
The possibility that this effect resul-
ted from a vasopressor action of eryt-
hropoietin seemed unlikely; baseline 
hemodynamic measurements in the 
group of rats that received erythropo-
ietin 15 minutes before induction of 
VF (EPOBL -15-min) demonstrated a 
statistically borderline decrease (not 
increase) in systemic vascular resistan-
ce from 1.092 ± 0.147 to 1.010 ± 0.133 
mm Hg/mL/min/kg (p = 0.077 by pai-
red t-test).
Defibrillation restored spontaneous cir-
culation in 8 EPOBL -15-min, 8 EPOVF 
10-min, and 9 controls. Post-resuscitati-
on, EPOVF 10-min rats had significantly 
higher mean aortic pressure associ-
ated with numerically higher cardiac 
index and higher peripheral vascular 
resistance. The diminished effectivene-
ss of erythropoietin when given before 
VF is intriguing and worthy of additional 
investigation.
Studies in humans: A clinical study was 
performed in collaboration with Dr. Šte-
fek Grmec, MD, PhD and colleagues at 
the Maribor Emergency Medical Servi-
ces (EMS) system in the city of Maribor 
and adjacent rural areas encompassing 
a population of approximately 200,000 
inhabitants. (43)
Resuscitation was attempted using 
regionally developed protocols that 
incorporate ILCOR 2005 recommenda-
tions by a two-tier system composed 
of basic life support (BLS) and advan-
ced life support (ALS) teams with the 
latter led by a physician. Upon arrival 
of the ALS team the trachea was intu-
bated – verifying proper placement by 
capnography  and positive pressure 
ventilation started with a tidal volume 
of approximately 6 ml/kg at 10 breaths 
per minute unsynchronized to compre-
ssions. The ALS team also established 
peripheral vascular access (within 
approximately 30 seconds). Patients 
assigned to erythropoietin received 
90,000 IU of beta-epoetin (NeoRecor-
mon, Hoffman La Roche) as a bolus 
within 1 or 2 minutes after starting chest 
compression followed by a 10-ml bolus 
of 0.9% NaCl. Beta-epoetin was kept 
refrigerated (2-8 °C) in the ambulance 
until immediately before use. In every 
instance erythropoietin was given befo-
re any other drug.
Patients who had return of spontane-
ous circulation were started on 0.9% 
NaCl solution cooled at 4°C (30 ml/
kg infused at 100 ml/min) and given 
0.08-0.10 mg/kg of vecuronium bro-
mide (Norcuron®, Organon) to initia-
te hypothermia while on route to the 
hospital. For hemodynamic stability, 
patients received dopamine (5-10 mcg/
kg/min) for systolic blood pressure <90 
mmHg, dobutamine (2.5-20.0 mcg/kg/
min) for suspected cardiogenic shock, 
or if systolic blood pressure remained 
< 70 mmHg despite the preceding 
measures norepinephrine (8-12 mcg/
kg/min).
Upon hospital arrival patients were 
directly admitted to the Intensive Care 
Unit (ICU). Patients were cooled to a 
core temperature between 32 and 34°C 
by external means until they regained 
consciousness or had completed 24 
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hours. Patients with ST-segment eleva-
tion myocardial infarction had percuta-
neous coronary interventions. Inotropic 
and vasopressor agents were infused 
guided by hemodynamic monitoring 
using a pulmonary artery catheter and 
transthoracic echocardiography.
Study groups: The study was originally 
designed as prospective and randomi-
zed. However, disruption in the supply 
of erythropoietin, prompted investiga-
tors to administer erythropoietin or 0.9% 
NaCl control based on availability, allo-
cating 24 patients to erythropoietin and 
30 to 0.9% NaCl between April 2007 
and May 2008. The control group for 
the analysis was designated as con-
current controls. Post-hoc, a second 
control group was included selecting 
48 patients out of 126 patients who had 
out-of-hospital cardiac arrest treated 
with the same resuscitation protocol 
the year before. These 48 patients were 
selected using propensity scores assi-
gning two controls for each erythropo-
ietin-treated patient. Propensity scores 
were calculated using multiple logistic 
regressions; entering age, male sex, 
witnessed arrest, time from call to start 
CPR (cardiopulmonary resuscitation), 
pulseless electrical activity, asystole, 
and bystander CPR as pre-treatment 
predictors of outcome. The control 
group was designated as matched 
controls. The same variables used to 
calculate propensity scores were used 
to adjust odds ratios for the comparison 
between erythropoietin and the concu-
rrent controls and between erythropoie-
tin and the matched controls.
Results: By univariate analysis, admi-
nistration of erythropoietin  when 
compared with concurrent controls  
was associated with higher rates of 
ICU admission, ROSC (resuscitation of 
spontaneous circulation), 24-hour sur-
vival, and survival to hospital discharge 
and  when compared with matched 
controls  it was associated with higher 
rates of ICU admission, ROSC, and 
24-hour survival. After adjustment for 
pretreatment covariates (listed above), 
comparison with concurrent controls 
reduced the odds ratio but retained sta-
tistical significance for ICU admission 
and ROSC whereas comparison with 
matched controls increased the odds 
ratio demonstrating statistical signifi-
cance for all four outcomes).
To assess whether the beneficial effects 
on resuscitation outcomes could have 
been linked to the beneficial effects 
on left ventricular myocardial disten-
sibility  as suggested by our prece-
ding study in rats (42)  we examine 
the effects on PETCO2. As discussed 
earlier, PETCO2 is a good surrogate 
measurement of forward blood flow 
during chest compression. (4,25-27) 
In the study, rescuers were trained and 
retrained to provide consistent depth 
and rate of compression and the values 
of PETCO2 in both control groups were 
already indicative of high quality chest 
compression. If  as hypothesized  
erythropoietin preserved myocardial 
distensibility, for a given compression 
depth, one would expect higher forward 
blood flow in the presence of erythro-
poietin and therefore higher PETCO2. 
This was indeed the case. Victims who 
received erythropoietin had signifi-
cantly higher PETCO2 during chest 
compression.
Because a single dose was admini-
stered, substantial effects on erythro-
poiesis were not anticipated. In fact, 
the hemoglobin and hematocrit in the 
present study were not statistically dif-
ferent than controls at 48 hours and at 
72 hours.
Accordingly, these clinical observations 
 though based on a small sample 
size  are consistent with the hypot-
hesis that erythropoietin  by preser-
ving myocardial distensibility  leads to 
hemodynamically more effective chest 
compression resulting in higher resus-
citation and survival rates. 
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